Navigation Links
Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
Date:8/14/2014

Austin. Despite widespread vaccination, Pertussis rates in the United States continue to rise steadily, and according to the World Health Organization, B. pertussis infection causes an estimated 300,000 deaths worldwide each year, primarily among young, unvaccinated infants.

Pertussis Operational Highlights and Upcoming Milestones:

  • Positive preclinical data reported from two non-human primate studies, supporting the association of SYN-005 with favorable decreases in white blood cell counts within two days and achievement of nearly normal levels within one week of treatment with SYN-005.
  • Research was highlighted last month at a Gordon Research Conference on Microbial Toxins and Pathogenicity by Synthetic Biologics' academic collaborator at The University of Texas at Austin, Jennifer Maynard, Ph.D.
  • Dr. Maynard to present Synthetic Biologics' SYN-005 mAb combination for the treatment of Pertussis in an oral presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on September 7th in Washington D.C.
  • Filing of IND and initiation of a Phase I clinical trial is expected during the first half of 2015. Topline data is expected within approximately 90 days of the start of the trial, after which a Phase II trial is planned, with topline results expected in the second half of 2015.
  • Orphan Drug designation request submitted for SYN-005 for the treatment of Pertussis.
  • Intend to initiate cGMP manufacturing of SYN-005 to support clinical studies.
  • Mr. Riley concluded, "We look forward to Dr. Voskuhl's presentation at the ACTRIMS-ECTRIMS meeting in September. Dr. Voskuhl is expected to provide details about the significant clinical outcome measures including relapse rate, disability, and cognition measures evaluated in this compelling Phase II trial. We believe the unique and differentiated anti-inflammatory, as well as neuroprote
    '/>"/>

    SOURCE Synthetic Biologics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
    2. Synthetic Biologics to Report Second Quarter 2014 Financial Results
    3. Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
    4. Global Synthetic Biology Market 2014-2018
    5. Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
    6. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
    7. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
    8. Synthetic Biologics Announces Proposed Public Offering of Common Stock
    9. Global Geosynthetics Market 2012-2016
    10. Process holds promise for production of synthetic gasoline
    11. Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
    (Date:12/19/2014)... CAMBRIDGE, MA (PRWEB) December 18, 2014 ... adults in the United States suffer from one or ... arthritis, asthma, or cancer. Medication can address some of ... to daily activities that many sufferers face. While implanted ... surgery and stimulate the whole nerve, which can induce ...
    (Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
    (Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
    Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
    ... CAMBRIDGE, Mass., Nov. 4 Genstruct Inc., ... mechanisms, networks and,biomarkers to better develop novel ... has become a member of The Biomarker ... Foundation for the,National Institutes on Health (FNIH), ...
    ... in specialty biologics development, TORONTO and CHARLOTTETOWN, ... Inc. have agreed to partner in the development ... treatments, with a goal of,advancing the project to ... to add to its portfolio of biologic products., ...
    ... Help Children Reach Normal Height, PRINCETON, N.J., Nov. ... them from growing to a normal height now have ... [rDNA origin] injection) for the treatment of short stature ... catch-up growth by,age 2-4 years., The U.S. Food ...
    Cached Biology Technology:Genstruct Added to The Biomarker Consortium's Rapidly Growing Roster of Industry Experts 2Genstruct Added to The Biomarker Consortium's Rapidly Growing Roster of Industry Experts 3Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 3FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 4FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 5
    (Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
    (Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
    (Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
    Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
    ... to reach a compromise that outlaws reproductive cloning or ... potential abuse, prejudice and discrimination, according to authors of ... Institute of Advanced Studies ( www.ias.unu.edu ). A ... clone, coupled with freedom for nations to permit strictly ...
    ... University of Western Ontario is set to host Canadas ... Exercise Physiology (CSEP) Annual Scientific Conference. The four-day, ... November 17 at the London Convention Centre, for the ... of the countrys leading thinkers in the fields of ...
    ... 2007 Researchers at Childrens Hospital of Pittsburgh of UPMC ... study the effectiveness of oral insulin in preventing or delaying ... for the disease. The researchers want to determine if ... onset of type 1 diabetes in relatives of people who ...
    Cached Biology News:Human clones: New U.N. analysis lays out world's choices 2Human clones: New U.N. analysis lays out world's choices 3Human clones: New U.N. analysis lays out world's choices 4Canadian Society of Exercise Physiology Annual Scientific Conference 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2
    LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...
    in vitro Translation, Accessory Products...
    ... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
    Sheep Serum US Origin...
    Biology Products: